SPA
FLNA

Sherbrooke Park Advisers’s Filana Therapeutics FLNA Stock Holding History

Sherbrooke Park Advisers’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-49,584
Closed -$117K – 893
2024
Q4 		$117K Buy
+49,584
New +$871K 0.04% 652

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sherbrooke Park Advisers's FLNA Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Filana Therapeutics (FLNA) in Q1 2025, closing a stake of 49,584 shares — an estimated $117K sold.

Sherbrooke Park Advisers first reported a position in FLNA in Q4 2024 and held it in 1 quarter. The position peaked at $117K in Q4 2024. 117 funds tracked by Wall St. Rank hold FLNA as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Filana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 49,584 Filana Therapeutics shares in Q1 2025, an estimated $117K.
  • Sherbrooke Park Advisers first reported a position in Filana Therapeutics in Q4 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Filana Therapeutics position peaked at $117K in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.